
how to prepare CCOC(=O)N1CC[C@H](NC(=O)c2cc(Cl)c(N)cc2OC)[C@H](OC)C1


思考了 7m 44s
我会先确认该结构及是否有对应文献或专利路线，再梳理实用途径，并重点核对取代哌啶环的立体化学控制。

规划了合成路线


已搜索 12 个网站

计算了目标分子的立体化学与分子式

核对了文献结构


已搜索 27 个网站

寻找准确出处


已搜索 37 个网站

整理了合成方案

核算关键步骤并汇总合成计划

完善了文献依据

收束检索范围

整合路线证据


已搜索 19 个网站

已找到直接先例：EP0076530A2 的 Example LXVIII 以 80% 收率得到外消旋 cis 产物，芳香 NH₂ 无需保护；目标 (3R,4S) 仍需拆分或手性前体。

整合立体化学路线并确定手性起点


已搜索 17 个网站

计算目标化合物及试剂分子式分子量


from rdkit import Chem
from rdkit.Chem import Descriptors, rdMolDescriptors
smi = "CCOC(=O)N1CC[C@H](NC(=O)c2cc(Cl)c(N)cc2OC)[C@H](OC)C1"
mol=Chem.MolFromSmiles(smi)
print(Chem.MolToSmiles(mol))
print(Chem.FindMolChiralCenters(mol, includeUnassigned=True))
print(rdMolDescriptors.CalcMolFormula(mol), Descriptors.MolWt(mol), rdMolDescriptors.CalcExactMolWt(mol))
for a in mol.GetAtoms():
    print(a.GetIdx(), a.GetSymbol(),a.GetChiralTag(), a.GetProp("_CIPCode") if a.HasProp("_CIPCode") else "", [n.GetIdx() for n in a.GetNeighbors()])
CCOC(=O)N1CC[C@H](NC(=O)c2cc(Cl)c(N)cc2OC)[C@H](OC)C1
[(8, 'S'), (22, 'R')]
C17H24ClN3O5 385.8480000000002 385.14044854799994
0 C CHI_UNSPECIFIED  [1]
1 C CHI_UNSPECIFIED  [0, 2]
2 O CHI_UNSPECIFIED  [1, 3]
3 C CHI_UNSPECIFIED  [2, 4, 5]
4 O CHI_UNSPECIFIED  [3]
5 N CHI_UNSPECIFIED  [3, 6, 25]
6 C CHI_UNSPECIFIED  [5, 7]
7 C CHI_UNSPECIFIED  [6, 8]
8 C CHI_TETRAHEDRAL_CCW S [7, 9, 22]
9 N CHI_UNSPECIFIED  [8, 10]
10 C CHI_UNSPECIFIED  [9, 11, 12]
11 O CHI_UNSPECIFIED  [10]
12 C CHI_UNSPECIFIED  [10, 13, 19]
13 C CHI_UNSPECIFIED  [12, 14]
14 C CHI_UNSPECIFIED  [13, 15, 16]
15 Cl CHI_UNSPECIFIED  [14]
16 C CHI_UNSPECIFIED  [14, 17, 18]
17 N CHI_UNSPECIFIED  [16]
18 C CHI_UNSPECIFIED  [16, 19]
19 C CHI_UNSPECIFIED  [18, 20, 12]
20 O CHI_UNSPECIFIED  [19, 21]
21 C CHI_UNSPECIFIED  [20]
22 C CHI_TETRAHEDRAL_CCW R [8, 23, 25]
23 O CHI_UNSPECIFIED  [22, 24]
24 C CHI_UNSPECIFIED  [23]
25 C CHI_UNSPECIFIED  [22, 5]

I would prepare this by coupling 4-amino-5-chloro-2-methoxybenzoic acid with the appropriate chiral 4-amino-3-methoxypiperidine. There is a direct precedent: EP0076530A2, Example LXVIII, compound 168, reports the same connectivity as a cis racemate in 80% isolated yield. Your SMILES specifies one enantiomer, so the stereochemical requirement must be addressed separately. 

1. Identify the exact target
Interpreting the stereochemistry in your SMILES gives:

Ethyl (3R,4S)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidine-1-carboxylate

The important structural features are the cis relationship between the piperidine methoxy and benzamido substituents, the specified (3R,4S) configuration, and the ethyl carbamate on the piperidine nitrogen.

Calculated from your SMILES: molecular formula C₁₇H₂₄ClN₃O₅, molecular weight 385.85 g/mol.

2. Recommended retrosynthetic disconnection
Disconnect the benzamide bond:

Target
   │
   └── Amide formation
          │
          ├── A: Ethyl (3R,4S)-4-amino-3-methoxypiperidine-1-carboxylate
          │
          └── B: 4-Amino-5-chloro-2-methoxybenzoic acid
Chiral amine A

CCOC(=O)N1CC[C@H](N)[C@H](OC)C1
Aromatic acid B

COc1cc(N)c(Cl)cc1C(=O)O
This disconnection keeps both stereocenters in a single building block. The final coupling does not require breaking or forming bonds at either stereogenic carbon.

3. Final coupling: an experimentally supported starting point
The following quantities are calculated by scaling the patent’s weight ratios to 1.00 mmol of amine A. Substituting enantiopure A for its racemate is a proposed adaptation, not a separately verified experiment. 

Component	Amount	Equivalents
Amine A, free base	202 mg	1.00
Acid B	238 mg	1.18
Triethylamine	125 mg	1.23
Ethyl chloroformate	137 mg	1.27
Chloroform	4.28 g for activation; 3.80 g for the amine solution	—
Procedure: Add triethylamine, then ethyl chloroformate, to B in chloroform below 10 °C. Stir 45 minutes below 10 °C, add A in chloroform at that temperature, then stir 18 hours at room temperature. The reported isolation uses aqueous washing and silica chromatography with chloroform/methanol 90:10. 

The aromatic NH₂ is unprotected in this precedent. Also, stop at compound 168: the subsequent patent example hydrolyses the ethyl carbamate, which your target must retain. 

My interpretation: this is the strongest first coupling experiment because it is based on the actual substrate combination, rather than a generic amide-coupling recommendation. I would not assume that the reported 80% yield transfers unchanged to a new scale, solvent, or starting-material specification.

4. How to obtain the correct chiral piperidine
This is the main route-selection decision.

Route A — Obtain the correct ethyl-carbamate amine, then couple
This is the shortest route:

Enantiopure (3R,4S) amine A + acid B
                    ↓
                  Target
For procurement or custom synthesis, specify the exact isomeric SMILES of A, not merely “cis-4-amino-3-methoxypiperidine.”

I would require documentation of both diastereomeric purity and enantiomeric purity. A material described as “cis, 98% purity” does not, by that description alone, establish that it is the desired single enantiomer.

I did not verify a dependable commercial listing for the exact (3R,4S), N-ethoxycarbonyl amine during this search.

Route B — Start with a commercially listed chiral Boc building block
I did find a listing for:

tert-Butyl (3R,4S)-4-amino-3-methoxypiperidine-1-carboxylate,
CAS 1363378-22-6, ChemScene CS-0048556.

This has the required stereochemical skeleton but a Boc group instead of the ethyl carbamate. The listing supports its identity as a procurement lead; batch availability and enantiomeric purity still need confirmation. 

A short proposed route from it is:

(3R,4S)-N-Boc-4-amino-3-methoxypiperidine
       │
       │  Couple the C4 amine with acid B
       ↓
N-Boc-protected benzamide
       │
       │  Remove Boc
       ↓
Benzamide with a free piperidine NH
       │
       │  Ethoxycarbonylate the piperidine nitrogen
       ↓
Target
The step that needs particular testing is the last carbamoylation. I would expect the aliphatic piperidine nitrogen to react preferentially over the aromatic amino group, but that is a chemoselectivity prediction, not a validated result for this sequence. Excess ethyl chloroformate could introduce unwanted additional carbamoylation.

A more conservative, longer design avoids that uncertainty by exchanging the protecting group before introducing the aromatic fragment:

Correct chiral N-Boc amine
 → protect the exocyclic NH2 as Cbz
 → remove the ring-N Boc group
 → install the ring-N ethyl carbamate
 → remove Cbz
 → amine A
 → couple with acid B
This is my proposed protecting-group strategy, not a sequence I found reported end-to-end. It also places any hydrogenolytic Cbz removal before the chlorinated aromatic fragment enters the route.

Route C — Make the cis racemate, then resolve it
For a small reference sample, I would also evaluate preparing the documented cis racemate and screening preparative chiral HPLC or SFC.

This avoids developing an asymmetric synthesis, but a suitable separation method and an absolute-configuration assignment are still required. Separating two peaks does not identify which one is (3R,4S).

There are stereochemical-resolution precedents in this compound family. However, the dibenzoyltartaric-acid resolution described in US7326787B2 isolates a protected (3S,4R) piperidine intermediate—the opposite configuration from your target. It should not be copied without checking the stereochemical outcome. 

5. Product verification
From the supplied structure, the calculated positive-ion HRMS value is:

[
M
+
H
]
+
=
386.1477
[M+H] 
+
 =386.1477
​
 
I would check the isolated material in three separate ways:

Question	Appropriate check
Is the connectivity correct, including retention of the ethyl carbamate?	NMR and LC–MS/HRMS
Is the piperidine substitution cis rather than trans?	Appropriate NMR stereochemical analysis and/or an assigned reference
Is it specifically the (3R,4S) enantiomer?	Chiral chromatography plus a reliable absolute-configuration assignment
An ordinary LC–MS result matching the expected mass is not sufficient to establish the requested stereochemistry.

My recommendation
First try to obtain enantiopure amine A and use the documented final coupling. That gives the cleanest, shortest route. The commercially listed (3R,4S) Boc analogue is the most concrete alternative starting-material lead I found.

The distinction is important: the final amide construction has a direct experimental precedent; obtaining and verifying the required (3R,4S) piperidine is the part that still needs to be secured for your exact SMILES. 




